FGFRi
6 abstracts
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative.Org: Massachusetts General Hospital, PRIME Education LLC,
Abstract
Generalizable FGFR prediction across tumor types using self supervised learning.Org: Janssen R & D, LLC, Los Angeles, CA, Janssen R&D, Janssen Research & Development,
Abstract
The impact of next generation sequencing on the management of urothelial cell carcinoma.Org: Long Island Jewish Forest Hills, Forest Hills Lab, Long Island Jewish Medical Center, Queens, NY, Northwell Health, New Hyde Park, NY,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,